HRP20100552T1 - Agonisti beta-2 adrenoceptora za liječenje kožnih bolesti vezivnog tkiva - Google Patents
Agonisti beta-2 adrenoceptora za liječenje kožnih bolesti vezivnog tkiva Download PDFInfo
- Publication number
- HRP20100552T1 HRP20100552T1 HR20100552T HRP20100552T HRP20100552T1 HR P20100552 T1 HRP20100552 T1 HR P20100552T1 HR 20100552 T HR20100552 T HR 20100552T HR P20100552 T HRP20100552 T HR P20100552T HR P20100552 T1 HRP20100552 T1 HR P20100552T1
- Authority
- HR
- Croatia
- Prior art keywords
- beta2
- adrenoceptor agonist
- alkyl
- preparation
- group
- Prior art date
Links
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 title claims abstract 42
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 title claims abstract 42
- 239000000556 agonist Substances 0.000 title 1
- 208000018631 connective tissue disease Diseases 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 claims abstract 41
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 14
- -1 C4-6-cycloalkyl Chemical group 0.000 claims abstract 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract 11
- 229940079593 drug Drugs 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 7
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims abstract 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical class 0.000 claims abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 5
- 150000001721 carbon Chemical group 0.000 claims abstract 5
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract 5
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 208000006802 Lupus erythematosus panniculitis Diseases 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims abstract 2
- 208000011830 chronic cutaneous lupus erythematosus Diseases 0.000 claims abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- 230000000699 topical effect Effects 0.000 claims abstract 2
- 239000000839 emulsion Substances 0.000 claims 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- TWUSDDMONZULSC-HZMBPMFUSA-N (1r,2s)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@@H](O)[C@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-HZMBPMFUSA-N 0.000 claims 2
- IRVLBORJKFZWMI-ZYHUDNBSSA-N (1s,2r)-2-[ethyl(methyl)amino]-1-phenylpropan-1-ol Chemical compound CCN(C)[C@H](C)[C@@H](O)C1=CC=CC=C1 IRVLBORJKFZWMI-ZYHUDNBSSA-N 0.000 claims 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical group CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims 2
- UWYLQWLJGMLJQF-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(butan-2-ylamino)ethanol Chemical compound CCC(C)NCC(O)C1=CC=C(N)C=C1 UWYLQWLJGMLJQF-UHFFFAOYSA-N 0.000 claims 2
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims 2
- XTJMTDZHCLBKFU-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-fluorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1F XTJMTDZHCLBKFU-UHFFFAOYSA-N 0.000 claims 2
- BUXRLJCGHZZYNE-UHFFFAOYSA-N 2-amino-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzonitrile Chemical compound CC(C)NCC(O)C1=CC=C(N)C(C#N)=C1 BUXRLJCGHZZYNE-UHFFFAOYSA-N 0.000 claims 2
- MPCPSVWSWKWJLO-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenol Chemical compound CC(C)NCC(O)C1=CC=C(O)C=C1 MPCPSVWSWKWJLO-UHFFFAOYSA-N 0.000 claims 2
- OVTZNVCECJYMDW-UHFFFAOYSA-N 4-[2-(cyclobutylamino)-1-hydroxyethyl]benzene-1,2-diol Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNC1CCC1 OVTZNVCECJYMDW-UHFFFAOYSA-N 0.000 claims 2
- RTLJQOLVPIGICL-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(methylsulfonylmethyl)phenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CS(C)(=O)=O)=C1 RTLJQOLVPIGICL-UHFFFAOYSA-N 0.000 claims 2
- KOTMQCNDGLTIHR-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-3-fluorophenol Chemical compound C1=NC2=CC=CC=C2N1CCC(C)(C)NCC(O)C1=CC=C(O)C=C1F KOTMQCNDGLTIHR-UHFFFAOYSA-N 0.000 claims 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 2
- RSDQHEMTUCMUPQ-UHFFFAOYSA-N 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]quinolin-8-ol Chemical compound C1=CC=C2C(C(O)CNC(C)C)=CC=C(O)C2=N1 RSDQHEMTUCMUPQ-UHFFFAOYSA-N 0.000 claims 2
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 2
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 claims 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 2
- ZSTCZWJCLIRCOJ-DGCLKSJQSA-N Zilpaterol Chemical compound O[C@H]1[C@H](NC(C)C)CCN2C(=O)NC3=CC=CC1=C32 ZSTCZWJCLIRCOJ-DGCLKSJQSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 229950004242 amiterol Drugs 0.000 claims 2
- 229960004620 bitolterol Drugs 0.000 claims 2
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 claims 2
- 229950009770 butaxamine Drugs 0.000 claims 2
- 229960001386 carbuterol Drugs 0.000 claims 2
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 claims 2
- 229950010971 cimaterol Drugs 0.000 claims 2
- 229960001117 clenbuterol Drugs 0.000 claims 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims 2
- PHSMOUBHYUFTDM-UHFFFAOYSA-N colterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(O)=C1 PHSMOUBHYUFTDM-UHFFFAOYSA-N 0.000 claims 2
- 229950004306 colterol Drugs 0.000 claims 2
- 229950010161 deterenol Drugs 0.000 claims 2
- 229960002267 ethylnorepinephrine Drugs 0.000 claims 2
- LENNRXOJHWNHSD-UHFFFAOYSA-N ethylnorepinephrine Chemical compound CCC(N)C(O)C1=CC=C(O)C(O)=C1 LENNRXOJHWNHSD-UHFFFAOYSA-N 0.000 claims 2
- 229960001022 fenoterol Drugs 0.000 claims 2
- 229950009061 flerobuterol Drugs 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 229960000708 hexoprenaline Drugs 0.000 claims 2
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 claims 2
- 229960004078 indacaterol Drugs 0.000 claims 2
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 2
- 229960001268 isoetarine Drugs 0.000 claims 2
- 229950004407 mabuterol Drugs 0.000 claims 2
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 claims 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 2
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 claims 2
- 229950008345 nardeterol Drugs 0.000 claims 2
- 229950000499 norbudrine Drugs 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 229960002657 orciprenaline Drugs 0.000 claims 2
- 229960005414 pirbuterol Drugs 0.000 claims 2
- 229960002288 procaterol Drugs 0.000 claims 2
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims 2
- 229950000298 quinprenaline Drugs 0.000 claims 2
- 229960002720 reproterol Drugs 0.000 claims 2
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims 2
- 229960001457 rimiterol Drugs 0.000 claims 2
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 claims 2
- 229960002052 salbutamol Drugs 0.000 claims 2
- 229950001879 salmefamol Drugs 0.000 claims 2
- 229960004017 salmeterol Drugs 0.000 claims 2
- 229950010289 soterenol Drugs 0.000 claims 2
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 claims 2
- 229950007862 sulfonterol Drugs 0.000 claims 2
- 229960000195 terbutaline Drugs 0.000 claims 2
- 229960000859 tulobuterol Drugs 0.000 claims 2
- 229960000960 zilpaterol Drugs 0.000 claims 2
- XJBCFFLVLOPYBV-UHFFFAOYSA-N zinterol Chemical compound C=1C=C(O)C(NS(C)(=O)=O)=CC=1C(O)CNC(C)(C)CC1=CC=CC=C1 XJBCFFLVLOPYBV-UHFFFAOYSA-N 0.000 claims 2
- 229950004209 zinterol Drugs 0.000 claims 2
- LIXBJWRFCNRAPA-NSHDSACASA-N 4-[(1r)-2-(tert-butylamino)-1-hydroxyethyl]-3-chlorophenol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C=C1Cl LIXBJWRFCNRAPA-NSHDSACASA-N 0.000 claims 1
- RDUHXGIIUDVSHR-UHFFFAOYSA-N bamethan Chemical compound CCCCNCC(O)C1=CC=C(O)C=C1 RDUHXGIIUDVSHR-UHFFFAOYSA-N 0.000 claims 1
- 229960004162 bamethan Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 1
- 229940039009 isoproterenol Drugs 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 229950001737 meluadrine Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- LUMAEVHDZXIGEP-UHFFFAOYSA-N protokylol Chemical compound C=1C=C2OCOC2=CC=1CC(C)NCC(O)C1=CC=C(O)C(O)=C1 LUMAEVHDZXIGEP-UHFFFAOYSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940041677 topical spray Drugs 0.000 claims 1
- 125000004953 trihalomethyl group Chemical group 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 206010015150 Erythema Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 231100000321 erythema Toxicity 0.000 abstract 2
- 238000007920 subcutaneous administration Methods 0.000 abstract 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500529 | 2005-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100552T1 true HRP20100552T1 (hr) | 2010-11-30 |
Family
ID=36703472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100552T HRP20100552T1 (hr) | 2005-04-13 | 2010-10-11 | Agonisti beta-2 adrenoceptora za liječenje kožnih bolesti vezivnog tkiva |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US8426475B2 (zh) |
| EP (1) | EP1719507B1 (zh) |
| JP (1) | JP5021621B2 (zh) |
| KR (1) | KR101355422B1 (zh) |
| CN (1) | CN101203214B (zh) |
| AR (1) | AR054249A1 (zh) |
| AT (1) | ATE473735T1 (zh) |
| AU (1) | AU2006233502B2 (zh) |
| BR (1) | BRPI0609361A2 (zh) |
| CA (1) | CA2604758C (zh) |
| CY (1) | CY1111541T1 (zh) |
| DE (1) | DE602006015387D1 (zh) |
| DK (1) | DK1719507T3 (zh) |
| EA (1) | EA016082B1 (zh) |
| ES (1) | ES2348920T3 (zh) |
| HK (1) | HK1091739A1 (zh) |
| HR (1) | HRP20100552T1 (zh) |
| IL (1) | IL186491A (zh) |
| MX (1) | MX2007012794A (zh) |
| MY (1) | MY147864A (zh) |
| NO (1) | NO331211B1 (zh) |
| NZ (1) | NZ562940A (zh) |
| PL (1) | PL1719507T3 (zh) |
| PT (1) | PT1719507E (zh) |
| RS (1) | RS51464B (zh) |
| SI (1) | SI1719507T1 (zh) |
| TW (1) | TWI366457B (zh) |
| WO (1) | WO2006108424A2 (zh) |
| ZA (1) | ZA200708748B (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0604826D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders and pain |
| WO2008006828A1 (en) * | 2006-07-10 | 2008-01-17 | Intervet International B.V. | Zilpaterol enantiomer compositions and methods of making and using such compositions |
| GB0624757D0 (en) * | 2006-12-12 | 2007-01-17 | Sosei R & D Ltd | Novel compounds |
| GB0805535D0 (en) * | 2008-03-27 | 2008-04-30 | Univ Leicester | Scar prevention |
| US20120252831A1 (en) * | 2011-03-31 | 2012-10-04 | Mustafa Nevzat Ilac Sanayii A.S. | Compositions of opioid antagonists and methods for treating scleroderma therewith |
| CN102267917B (zh) * | 2011-06-15 | 2013-07-31 | 浙江工业大学 | 一种盐酸甲氧那明的合成方法 |
| UA115445C2 (uk) * | 2012-05-18 | 2017-11-10 | Інтервет Інтернешнл Б.В. | Спосіб збільшення приросту бройлерних курей |
| GB2513297A (en) * | 2013-03-08 | 2014-10-29 | Univ Leicester | Methods |
| CN104606177B (zh) * | 2014-11-21 | 2018-02-02 | 苏州君宁新药开发中心有限公司 | 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用 |
| WO2018000098A1 (en) * | 2016-06-30 | 2018-01-04 | Cipher Pharmaceuticals Inc. | Treatment of inflammatory myopathies |
| CN106580978A (zh) * | 2016-11-30 | 2017-04-26 | 郑州仁宏医药科技有限公司 | 一种治疗皮炎的西药组合物及其应用 |
| WO2019032147A1 (en) * | 2017-08-10 | 2019-02-14 | Avro Life Sciences, Inc. | TRANSDERMAL DRUG DELIVERY SYSTEM |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| JP2022527769A (ja) * | 2019-03-27 | 2022-06-06 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニスト及びそれを使用する方法 |
| US11607395B2 (en) | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| CN112300237A (zh) * | 2020-04-13 | 2021-02-02 | 苏州恩泰新材料科技有限公司 | 海豹胆酸的制备方法及其应用 |
| CA3196808A1 (en) * | 2020-10-09 | 2022-04-14 | Mc2 Therapeutics Ltd | Treatment of dermatological conditions |
| CN116236467B (zh) * | 2023-02-07 | 2023-10-27 | 中国人民解放军总医院 | 西马特罗或其衍生物的新用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA7464B (en) | 1973-01-16 | 1974-11-27 | J Voorhees | Treatment of proliferating skin diseases with papavine alkaloids |
| US4284623A (en) * | 1979-11-09 | 1981-08-18 | Beck Lee R | Method of treating inflammation using bovine milk |
| SU895445A1 (ru) * | 1980-05-15 | 1982-01-07 | Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова | Способ лечени кожных форм красной волчанки |
| US4574129A (en) | 1984-01-31 | 1986-03-04 | Bristol-Myers Company | Topical nonsteroidal anti-inflammatory methods |
| JPS61154201A (ja) | 1984-12-26 | 1986-07-12 | Matsushita Electric Ind Co Ltd | 誘電体フイルタ |
| US4699777A (en) | 1985-08-21 | 1987-10-13 | Schering Corporation | Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea |
| PH25150A (en) | 1986-06-05 | 1991-03-13 | Ciba Geigy Ag | Novel pharmaceutical preparation for topical application |
| US4980159A (en) | 1989-05-23 | 1990-12-25 | Bristol-Myers Squibb Company | Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects |
| RU2092105C1 (ru) * | 1989-11-20 | 1997-10-10 | Нижегородский научно-исследовательский кожно-венерологический институт | Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой |
| DE4014252A1 (de) | 1990-05-04 | 1991-11-07 | Boehringer Ingelheim Vetmed | Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer |
| US5919827A (en) | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol |
| EP0540670B1 (en) | 1990-07-26 | 1996-03-20 | Monsanto Company | Method for preparation of crosslinked polyamines |
| GB9107196D0 (en) | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
| US5795564A (en) | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| JP3294876B2 (ja) | 1992-07-20 | 2002-06-24 | トキコ株式会社 | 給油装置 |
| AU1533495A (en) | 1994-01-12 | 1995-08-01 | Byk Nederland Bv | Phenyl ethanol amine ethers and uses thereof as beta-adreno-receptor agonists |
| JPH07304647A (ja) | 1994-05-09 | 1995-11-21 | Kao Corp | マッサージ用組成物 |
| GB9422306D0 (en) * | 1994-11-04 | 1994-12-21 | Sandoz Ltd | Organic compounds |
| GB9510162D0 (en) * | 1995-05-19 | 1995-07-12 | Bouras Elias | Compositions for the treatment of skin conditions |
| JPH09110674A (ja) | 1995-10-16 | 1997-04-28 | Kao Corp | 浴用剤組成物 |
| FR2740040B1 (fr) | 1995-10-23 | 1997-12-05 | Oreal | Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p |
| NZ500250A (en) * | 1997-04-30 | 2001-03-30 | Bridge Pharma Inc | Adrenergic beta-2 agonist eutomers, feed compositions and use for increasing muscle and decreasing fat |
| US6254882B1 (en) | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol |
| US6545007B2 (en) | 2000-11-17 | 2003-04-08 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines |
| CA2421893A1 (en) * | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| KR100973665B1 (ko) | 2001-12-03 | 2010-08-04 | 와이어쓰 엘엘씨 | 세포질 포스포리파제 ａ2의 억제제 |
| EP1496917B1 (en) * | 2002-04-19 | 2005-12-07 | Astion Development A/S | Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| WO2003088997A2 (en) | 2002-04-22 | 2003-10-30 | Universiteit Utrecht Holding B.V. | Reduction of unwanted immune reactions |
| WO2003092617A2 (en) | 2002-05-03 | 2003-11-13 | Combinatorx, Incorporated | Combinations for the treatment of inflammatory skin disorders |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US20040229849A1 (en) | 2002-09-24 | 2004-11-18 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20040220153A1 (en) | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| BR0314713A (pt) * | 2002-09-24 | 2005-07-26 | Combinatorx Inc | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias |
| JP4457017B2 (ja) * | 2002-12-20 | 2010-04-28 | アムジエン・インコーポレーテツド | 喘息及びアレルギー性炎症モジュレーター |
| PL378108A1 (pl) * | 2003-02-14 | 2006-03-06 | Combinatorx, Incorporated | Leczenie łączone do terapii zapalnych zaburzeń immunologicznych |
| EP1613266A4 (en) * | 2003-04-15 | 2009-05-06 | Theraquest Biosciences Llc | METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF |
| WO2005004852A1 (en) | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Pharmaceutical formulations |
| US20050192261A1 (en) | 2003-09-15 | 2005-09-01 | Jost-Price Edward R. | Methods and reagents for the treatment of immunoinflammatory disorders |
| AU2004292445B2 (en) * | 2003-11-21 | 2010-02-04 | Zalicus Inc. | Methods and reagents for the treatment of inflammatory disorders |
| US20070179181A1 (en) | 2004-03-17 | 2007-08-02 | Baxter Andrew D | Treatment of inflammatory disorders and pain using beta-aminoalcohols |
| WO2005102296A2 (en) | 2004-04-23 | 2005-11-03 | Heptagen Limited | Combinations for the treatment of immunoproliferative skin disorders such as psoriasis |
| EP1786410A2 (en) * | 2004-09-07 | 2007-05-23 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain |
-
2006
- 2006-04-12 ES ES06007632T patent/ES2348920T3/es active Active
- 2006-04-12 WO PCT/DK2006/050013 patent/WO2006108424A2/en active Application Filing
- 2006-04-12 RS RSP-2010/0442A patent/RS51464B/en unknown
- 2006-04-12 CA CA2604758A patent/CA2604758C/en not_active Expired - Fee Related
- 2006-04-12 PL PL06007632T patent/PL1719507T3/pl unknown
- 2006-04-12 MY MYPI20061656A patent/MY147864A/en unknown
- 2006-04-12 CN CN2006800165347A patent/CN101203214B/zh not_active Expired - Fee Related
- 2006-04-12 TW TW095112980A patent/TWI366457B/zh not_active IP Right Cessation
- 2006-04-12 DK DK06007632.0T patent/DK1719507T3/da active
- 2006-04-12 SI SI200630807T patent/SI1719507T1/sl unknown
- 2006-04-12 BR BRPI0609361-2A patent/BRPI0609361A2/pt not_active Application Discontinuation
- 2006-04-12 KR KR1020077026406A patent/KR101355422B1/ko active IP Right Grant
- 2006-04-12 MX MX2007012794A patent/MX2007012794A/es active IP Right Grant
- 2006-04-12 AU AU2006233502A patent/AU2006233502B2/en not_active Ceased
- 2006-04-12 JP JP2008505738A patent/JP5021621B2/ja not_active Expired - Fee Related
- 2006-04-12 DE DE602006015387T patent/DE602006015387D1/de active Active
- 2006-04-12 AR AR20060101443A patent/AR054249A1/es not_active Application Discontinuation
- 2006-04-12 AT AT06007632T patent/ATE473735T1/de active
- 2006-04-12 PT PT06007632T patent/PT1719507E/pt unknown
- 2006-04-12 EA EA200702204A patent/EA016082B1/ru not_active IP Right Cessation
- 2006-04-12 EP EP06007632A patent/EP1719507B1/en active Active
- 2006-04-12 NZ NZ562940A patent/NZ562940A/en not_active IP Right Cessation
- 2006-04-12 US US11/402,255 patent/US8426475B2/en active Active
- 2006-11-10 HK HK06112361.0A patent/HK1091739A1/xx not_active IP Right Cessation
-
2007
- 2007-10-08 IL IL186491A patent/IL186491A/en active IP Right Grant
- 2007-10-12 ZA ZA200708748A patent/ZA200708748B/xx unknown
- 2007-11-02 NO NO20075527A patent/NO331211B1/no not_active IP Right Cessation
-
2010
- 2010-10-11 HR HR20100552T patent/HRP20100552T1/hr unknown
- 2010-10-14 CY CY20101100919T patent/CY1111541T1/el unknown
-
2013
- 2013-04-22 US US13/867,796 patent/US20130237607A1/en not_active Abandoned
-
2017
- 2017-02-23 US US15/440,803 patent/US9907765B2/en not_active Expired - Fee Related
-
2018
- 2018-12-21 US US16/228,920 patent/US20190125699A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100552T1 (hr) | Agonisti beta-2 adrenoceptora za liječenje kožnih bolesti vezivnog tkiva | |
| JP2008535873A5 (zh) | ||
| ES2302350T3 (es) | Combinacion sinergica de inhibidores de pde y agonistas de adenilatociclasa o agonistas de guanililciclasa. | |
| KR880000091A (ko) | 국소용 약제학적 조성물 이의 제조방법 및 이의 용도 | |
| RU97115893A (ru) | Препарат местного применения | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| US20150374759A1 (en) | Method for Treatment of Sores and Lesions of the Skin | |
| AR037629A1 (es) | Formulaciones farmaceuticas que comprenden un derivado de platino | |
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| DE50310486D1 (de) | Lipid-transferprotein - systeme und deren kosmetische dermatologische anwendung | |
| JP2006527234A5 (zh) | ||
| RU2005128132A (ru) | Лечение бактериальных заболеваний органов дыхания путем местного применения фторхинолонов | |
| DE60230629D1 (de) | Verwendung von 2,5-dihydroxybenzolsulfonsäure-derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion | |
| KR910021238A (ko) | 켈로이드 치료제 | |
| KR900017588A (ko) | 상승효과를 나타내는 배합물 및 이의 치료제로서의 용도 | |
| RU2003103757A (ru) | Жидкая лекарственная форма налтрексона | |
| TH87784B (th) | สูตรเฉพาะที่มี o-เดสเมทธิลเวนลาฟาซีน(odv)หรือเกลือของมัน | |
| HUP0000552A2 (hu) | Egy O-(3-piperidino-2hidroxi-1-propil)-hidroximsav halogenidszármazék, annak alkalmazása, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény | |
| BR0204185A (pt) | Uso de substâncias agonistas de canais de k+ para prevenir ou tratar danos teciduais promovidos por ácido metil-malÈnico, composição farmacêutica compreendendo substâncias agonistas, composição para o tratamento ou prevenção de danos teciduais, composição compreendendo o uso de substâncias agonistas para uso no tratamento ou prevenção de danos teciduais, bem como composições apresentáveis em quaisquer formas farmacêuticas compreendendo substância agonista para uso no tratamento ou prevenção de danos teciduais | |
| Pampattiwar et al. | Selection of medicinal plants for the management of diabetic foot ulcer; an ayurvedic approach | |
| RU2005140963A (ru) | Лечебно-профилактическое средство "эйхлофил", его применение и способ профилактики и лечения заболеваний | |
| AR041767A1 (es) | Composicion de aplicacion topica para el tratamiento de ectoparasitos | |
| RU94016334A (ru) | Способ лечения половых расстройств при хроническом простатите | |
| DE202011050757U1 (de) | Pharmazeutisches Mittel |